|Videos|July 14, 2020

Complicating the Coronavirus Lockdown Debate

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

An equitable COVID-19 response must address long-standing and pandemic infectious disease emergencies simultaneously to succeed at preventing health care systems from becoming overwhelmed. Disruptions caused by the COVID-19 pandemic and its response could catalyze a surge in HIV, malaria, and tuberculosis (TB) deaths, according to a new modeling study published in The Lancet Global Health by authors from Imperial College London.

While concern has been raised about the relationship between these disruptions and other health priorities before, the new model focuses on where the worst impact would be felt: low- and middle-income countries. Their modeling seems to suggest that at current pace HIV, TB, and malaria deaths could increase by as much as 10%, 20%, and 36% respectively over the next 5 years due to the disruption of health services.

The models indicate that the stability of programs which address long standing infectious disease health burdens are at risk. In areas with substantial prior health care resource strains, the authors even note that years of life lost (defined as the number of years a person would have been expected to live had they not died of a particular cause) could in some cases be of similar scale to the biological impact of the pandemic itself. The COVID-19 pandemic has caused substantial disruptions by overwhelming struggling health systems, and through lockdown measures limiting routine health care activity and patient care-seeking. The demobilization of many sectors of industry has also lead to interruptions in medical supply chains.

For more on this story, Contagion spoke with co-lead author Professor Timothy Hallett of Imperial College London, UK. Hallett was careful to clarify that predicting the future impact of the ongoing COVID-19 pandemic is challenging, including due to ongoing uncertainty around the novel virus itself.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.